Emory University purchased a new stake in shares of Orchard Therapeutics PLC – (NASDAQ:ORTX) during the first quarter, HoldingsChannel.com reports. The firm purchased 156,401 shares of the company’s stock, valued at approximately $2,796,000. Orchard Therapeutics accounts for approximately 2.0% of Emory University’s investment portfolio, making the stock its 6th largest holding.
A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in ORTX. Parametric Portfolio Associates LLC raised its holdings in shares of Orchard Therapeutics by 76.8% in the first quarter. Parametric Portfolio Associates LLC now owns 57,310 shares of the company’s stock worth $1,025,000 after buying an additional 24,891 shares during the last quarter. TD Asset Management Inc. raised its holdings in shares of Orchard Therapeutics by 7.7% during the first quarter. TD Asset Management Inc. now owns 44,949 shares of the company’s stock worth $804,000 after purchasing an additional 3,200 shares during the last quarter. Lindbrook Capital LLC purchased a new position in shares of Orchard Therapeutics during the first quarter worth $53,000. Legacy Advisors LLC purchased a new position in shares of Orchard Therapeutics during the first quarter worth $53,000. Finally, Norges Bank purchased a new position in shares of Orchard Therapeutics during the fourth quarter worth $629,000. Institutional investors and hedge funds own 57.01% of the company’s stock.
Shares of Orchard Therapeutics stock opened at $18.61 on Monday. Orchard Therapeutics PLC – has a 1 year low of $8.65 and a 1 year high of $21.64. The firm has a market cap of $1.60 billion and a P/E ratio of -1.82.
Several brokerages recently issued reports on ORTX. Wedbush reissued an “outperform” rating and set a $25.00 target price on shares of Orchard Therapeutics in a report on Friday, March 22nd. Zacks Investment Research raised shares of Orchard Therapeutics from a “hold” rating to a “buy” rating and set a $19.00 target price for the company in a report on Wednesday, March 27th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $23.40.
COPYRIGHT VIOLATION WARNING: This story was first reported by Zolmax and is the property of of Zolmax. If you are viewing this story on another publication, it was stolen and reposted in violation of US & international copyright and trademark legislation. The legal version of this story can be read at https://zolmax.com/investing/emory-university-takes-2-80-million-position-in-orchard-therapeutics-plc-ortx/3096642.html.
About Orchard Therapeutics
Orchard Therapeutics plc, integrated biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified drug product to treat the patient's disease through a single administration.
Further Reading: How does a security become overbought?
Want to see what other hedge funds are holding ORTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Orchard Therapeutics PLC – (NASDAQ:ORTX).
Receive News & Ratings for Orchard Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orchard Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.